Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.54 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | ALPI | P09923 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065987 | 0.88 | PDE10A (0.58) | PDE10AAHRSCN5ADPP4DPP8 | |
| SCHEMBL18819912 | 0.85 | PDE10A (0.41) | PDE10AAHRKDM4ECYP11B2PDCD1 | |
| SCHEMBL17234784 | 0.81 | PDE10A (0.40) | PDE10AAHRKDM4EPTGS2ALPI | |
| SCHEMBL12844138 | 0.79 | PDE10A (0.36) | PDE10AAHRKDM4EPDCD1CD274 | |
| SCHEMBL12962511 | 0.78 | PDE10A (0.45) | PDE10AAHRSCN5ADPP4DPP8 | |
| SCHEMBL2066163 | 0.78 | PDE10A (0.50) | PDE10AAHRKDM4EPDCD1CD274 | |
| SCHEMBL2067920 | 0.78 | PDE10A (0.34) | PDE10AAHRKDM4ECYP11B2PDCD1 | |
| SCHEMBL13080295 | 0.77 | PDE10A (0.38) | PDE10AAHRSCN5AKDM4E | |
| SCHEMBL3151360 | 0.76 | DYRK1A (0.50) | PDE10AAHRKDM4EPDCD1CD274 | |
| SCHEMBL2067911 | 0.75 | AHR (0.38) | PDE10AAHRKDM4EPDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | PTAFR, PAFAH1B2, PAFAH1B3 | PDE10A 1664/4885AHR 486/4885SCN5A 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.